Shared 3D Genome Networks May Explain Why Fatigue Cuts Across Five Disorders
Chronic fatigue has long resisted tidy diagnosis because the same crushing exhaustion appears after viral infection, trauma, autoimmune inflammation, and neurologic disease. A new analysis from the University of East Anglia and Oxford BioDynamics argues that the common thread may not be the trigger itself, but the biological circuitry that follows it. In a study published in the Journal of Translational Medicine, researchers mapped 3D genome architecture across long Covid, ME/CFS, PTSD, rheumatoid arthritis and multiple sclerosis and found converging regulatory networks tied to immune signaling, metabolism, mitochondrial energy production and stress-response pathways.
The work does not claim that these disorders are the same disease. It makes a narrower and more provocative case: distinct illnesses may reach a similar clinical endpoint by disrupting overlapping systems that govern cellular resilience, inflammatory control and energy balance.
One sentence captures the clinical weight of the finding. Five different diagnoses may be feeding the same fatigue biology.
Prof Dmitry Pshezhetskiy, who led the research at UEA’s Norwich Medical School, framed the problem in practical terms. ME/CFS often follows infection. Long Covid develops after SARS-CoV-2. PTSD follows psychological trauma. Rheumatoid arthritis and multiple sclerosis arise from autoimmune injury. Yet patients with all five conditions frequently describe the same syndrome at the bedside: overwhelming fatigue, brain fog, poor concentration, disturbed sleep, autonomic dysfunction and marked loss of function.
Why Linear Gene Lists Miss the Shared Biology
The analysis moved beyond linear DNA sequence and focused on how the genome folds inside the cell. Using Oxford BioDynamics’ EpiSwitch Orion platform, the team examined 3D genomic organization, where distant stretches of DNA can physically contact each other and influence gene activity. In this framework, the relevant biology is not just which genes are present, but which genes are brought into regulatory reach by chromatin folding.
The data set was computational rather than based on newly recruited patients. The investigators combined previously published genomic information for long Covid, PTSD, rheumatoid arthritis and multiple sclerosis from genome-wide association studies with 3D genomic data from an earlier study of people with ME/CFS. That design matters because it tests whether different disorders that appear unrelated in standard genetic analyses might still converge when the genome is viewed as a spatial system.
At the level of individual genes, the overlap was surprisingly thin. Across the five conditions, there was little direct gene-by-gene convergence. The signal sharpened only when the researchers examined how those genes interacted in broader biological networks. Suddenly, the diseases no longer looked separate. They appeared to connect through the same immune, metabolic and stress-regulation circuits.
The biology fits the symptom pattern. Chronic fatigue is rarely just tiredness. It often behaves like a systems disorder in which immune activation, altered energy production and neuroendocrine stress responses begin to reinforce one another. A prolonged inflammatory state can drain mitochondrial efficiency. Disturbed stress-hormone signaling can further impair immune balance. When those loops persist, everyday exertion can become disproportionately costly.
Immune Dysregulation and Mitochondrial Stress Sit at the Center
The shared networks pointed to several major pathways: immune and inflammatory signaling, mitochondrial energy production, metabolic regulation, stress-response mechanisms and neuroendocrine signaling. In clinical terms, those are the systems most likely to produce the combination of exhaustion, cognitive fog and exercise intolerance reported by patients across these diagnoses.
The researchers also identified candidate “hub genes” located at especially active points in the shared networks. These included genes associated with immune regulation, inflammatory signaling and mitochondrial energy production. The study treats them as candidates, not confirmed disease drivers, and further validation will be needed before any one gene can be assigned causal weight.
A focused ME/CFS analysis drew attention to LAG3, a molecule linked to T-cell exhaustion. In that state, immune cells become less effective after prolonged activation. If future work confirms the association, LAG3 could help explain why some patients remain ill long after the original trigger has passed. Persistent immune activation would not need to remain dramatic to be harmful; chronic, low-grade dysfunction can still distort energy metabolism and leave patients depleted.
The signal is biologically plausible. Ongoing immune stimulation consumes resources, alters cytokine signaling and can push the body toward a metabolically expensive, inefficient steady state. In that setting, the patient may look normal on a routine exam while still being unable to sustain ordinary activity.
Blood Tests Could Replace Symptom-Only Diagnosis
The most immediate clinical appeal lies in diagnosis. ME/CFS and long Covid are still diagnosed largely through symptoms, and no universally accepted laboratory test exists for either condition. For patients, that often means years of uncertainty, repeated consultations and fragmented explanations that do little to explain the depth of impairment.
Previous work with the EpiSwitch platform had already produced a blood-based ME/CFS test with promising diagnostic accuracy, although it still requires further validation before clinical use. The new study extends that concept by suggesting that shared biological signatures may not be restricted to a single syndrome. If the same 3D genomic features can be identified across several fatigue-related disorders, blood-based tools may eventually help distinguish biological subtypes rather than forcing patients into symptom-only categories.
Objective testing would also change how these illnesses are framed. A positive assay would not erase clinical complexity, but it could anchor the diagnosis in measurable biology instead of leaving patients dependent on exclusion and pattern recognition alone.
The Path to Treatment Still Runs Through Validation
The therapeutic implications are promising but still early. If shared pathways truly sit upstream of fatigue across long Covid, ME/CFS, PTSD, rheumatoid arthritis and multiple sclerosis, they could become targets for treatments that work across diagnostic labels. The likely first step, however, is not a drug trial. It is replication.
This was a computational study built from existing genomic data, and that makes independent confirmation essential. The candidate genes and network signatures need to be tested in larger, prospectively collected cohorts and linked to clinical outcomes before they can be translated into routine care. The same is true for any future blood test built on this platform. Diagnostic enthusiasm without validation would be premature.
Still, the conceptual shift is substantial. The study argues that chronic exhaustion may be the outward expression of a deeper systems failure involving immune function, metabolism and stress-response biology. Different triggers may start the process, but the downstream circuitry may look strikingly similar once the illness is established.
For clinicians, that could eventually change how chronic fatigue syndromes are classified and investigated. For patients, it offers a more coherent explanation for why disorders that seem unrelated on paper can feel indistinguishable in everyday life.